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Abstract
Background: Antiplatelet therapy may attenuate the undesirable effects of platelets on the inflammatory cascades
in critical illness. The objective of this study was to evaluate the association between aspirin therapy during
intensive care unit (ICU) stay and all-cause mortality.
Methods: This was a nested cohort study within two randomized controlled trials in which all enrolled patients (N = 763)
were grouped according to aspirin intake during ICU stay. The primary endpoints were all-cause ICU mortality and
hospital mortality. Secondary endpoints included the development of severe sepsis during the ICU stay, ICU and hospital
length of stay and the duration of mechanical ventilation. Propensity score was used to adjust for clinically and statistically
relevant variables.
Results: Of the 763 patients, 154 patients (20 %) received aspirin. Aspirin therapy was not associated with a reduction in ICU
mortality (adjusted OR 1.18, 95 % CI 0.69–2.02, P = 0.55) nor with hospital mortality (adjusted OR 0.95, 95 % CI 0.61–1.50,
P = 0.82). Aspirin use had no preferential association with mortality among any of the study subgroups. Additionally, aspirin
therapy was associated with higher risk of ICU-acquired severe sepsis, and increased mechanical ventilation duration and ICU
length of stay.
Conclusion: Our study showed that the use of aspirin in critically ill patients was not associated with lower mortality, but
rather with an increased morbidity.
Trial Registration Number: ISRCTN07413772 and ISRCTN96294863.
Keywords: Aspirin, Outcome assessment, Intensive care, Hospital mortality, Survival, Multiple organ failure, and Propensity scores
Background
Sepsis and multiple organ failure (MOF) are the main
causes of death in intensive care units (ICUs). There is
ample evidence that platelets play an important role in
the progression of MOF in critically ill patients [1–5]. At
cellular level, platelets have a significant influence on in-
flammatory processes by releasing cytokines, chemokines,
and lipid mediators that have pro- or anti-inflammatory
properties [6–11], activating the complement system
[12, 13]. Other platelet effects include releasing anti-
microbial proteins and together with neutrophils
trapping bacteria [10, 14–17] and mediating adhesion
to monocytes, neutrophils, and endothelial cells that
lead to cellular functions such as production of
cytokines, and reactive oxygen as well as recruitment and
immigration of leukocytes at the site of tissue damage
[7, 10, 11, 18]. Hence, the question arose whether aspirin
may have a beneficial effect in critically ill patients.
Several observational studies have shown that anti-
platelet drugs reduce such biomarkers as C-reactive
protein, soluble CD62P, and CD54, pro-inflammatory
cytokines, and platelet leukocyte conjugate in these
patients [19–23]. The aim of the study was to assess the
association between aspirin therapy during ICU admission
and all-cause mortality in a cohort of critically ill medical-
surgical patients.
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The study was a retrospective cohort study, conducted
in the adult medical-surgical ICU at King Abdulaziz
Medical City, a tertiary-care academic referral center in
Riyadh, Saudi Arabia. The ICU admitted medical, surgi-
cal, and trauma patients, and operated as a closed unit
with 24-h, 7-day onsite coverage by critical care board
certified intensivists [24]. The nurse-to-patient ratio in
the unit was approximately 1:1.2.
Study design
This was a post-hoc analysis of two randomized controlled
Trials (ISRCTN07413772 and ISRCTN96294863). The
first trial was conducted between January 2004 and March
2006. It included 523 patients, comparing intensive insulin
therapy (IIT) (for patients with a blood glucose level of
4.4–6.1 mmol/L or 80–110 mg/dl) to conventional insulin
therapy (CIT) (for patients with a blood glucose level of
10–11.1 mmol/L or 180–200 mg/dl) [25]. The trial
showed no significant difference in ICU mortality between
the IIT and CIT groups (13.5 % vs. 17.1 %, p = 0.3).
Hypoglycemia occurred more frequently with intensive in-
sulin therapy (28.6 % vs. 3.1 % of patients; p = 0.0001)
[23]. The second trial, conducted between April 2006 and
January 2008, included 240 patients and assessed the ef-
fects on outcomes of permissive underfeeding (a caloric
goal of 60–70 % of the calculated requirement) versus tar-
get feeding (caloric goal of 90–100 % of the calculated re-
quirement) with either IIT or CIT in critically ill patients
[26]. The study found no difference between the two
groups in 28-day mortality (18 % vs. 23 %, p = 0.34) [26].
However, hospital mortality was lower in the permissive
underfeeding compared with the target-feeding group (30
% vs. 43 %, p = 0.04) [26]. All the patients enrolled in the
original two trials were included in this study. In brief,
these patients were ≥18 year-old with expected ICU length
of stay(LOS) of >48 h. Patients who were pregnant, had
do-not-resuscitate status within 24 h of admission, were
terminally ill or admitted to the ICU after cardiac arrest,
seizures, liver transplantation or burn injury were ex-
cluded. This study was approved by the Ministry of
National Guard Health Affairs (NGHA) /King Abdul-
lah International Medical Research Center (KAIMRC)
Institutional Review Board. The consent for the present
analysis was waived because of the observational nature of
the study.
Aspirin therapy
Data of aspirin therapy in the ICU were collected from
the Pharmaceutical Care database and was matched and
combined with the original clinical database. Aspirin
therapy was either as a continuation of a pre-ICU pre-
scription or a newly prescribed medication in the ICU
per the treating team discretion, such as for patients
admitted with stroke or acute coronary syndrome.
Data collection
The following data were retrieved from the two original
studies: age, gender, Acute Physiology and Chronic
Health Evaluation (APACHE II) score [27], sequential
organ failure assessment (SOFA) score [28], chronic co-
morbidities (chronic liver, chronic cardiovascular, chronic
respiratory, chronic renal and chronic immunocomprom-
ised) as defined by the APACHE II system, history of
diabetes mellitus, admission diagnosis category (re-
spiratory, cardiovascular, neurological, other medical,
non-operative trauma and post-operative), mechanical
ventilation (MV), sepsis and severe sepsis on admission.
We also documented the statin use, bilirubin level, serum
creatinine level, admission Glasgow Coma Scale (GCS)
score [28], vasopressor use, The arterial partial pressure of
O2 and the fraction of inspired oxygen (PaO2/FiO2) ratio,
international normalization ratio (INR), and platelet
count.
Outcomes
The primary outcomes were all-cause ICU mortality and
hospital mortality. Secondary endpoints included the de-
velopment of severe sepsis during the ICU stay, ICU and
hospital LOS, and MV duration.
Statistical analysis
Statistical analysis was carried out using the Statistical
Analysis Software (SAS, release 9, SAS Institute, Cary,
NC, 2005). We compared patients who received aspirin
during their ICU admission (aspirin group) to those who
did not (non-aspirin group). Categorical data were pre-
sented as frequency with percent, whereas continuous
variables were presented as mean with and standard de-
viation. Baseline characteristics and outcome variables
were compared using the Chi-square test for nominal
data and the Student t -test for continuous data. Due to
the non-random allocation to aspirin use and significant
differences between the groups in terms of baseline
characteristics, a propensity score was calculated using
the variables related to the aspirin exposure and out-
come. These variables were age, sex, diabetes history, ad-
mission category, APACHE II score, chronic respiratory
disease, chronic renal disease, chronic immunosuppres-
sion, creatinine, PaO2/FiO2 ratio, platelets, and statins
Furthermore, the association between aspirin therapy
each outcome was assessed by performing multivariate lo-
gistic regression analysis adjusting for the generated pro-
pensity score. Additionally, we carried out stratified
analyses by age, gender, admission category, APACHE II,
history of diabetes, the presence of chronic cardiac disease,
vasopressor therapy, sepsis, severe sepsis and septic shock,
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creatinine, platelet count, bilirubin, INR, GCS, ICU LOS
stay, MV, PaO2/FiO2 ratio, and the type of statins to detect
any effect modification of the association between aspirin
therapy and different outcome measures based on any of
these factors. The medians of the continuous variables
were used for categorization. The results of the multivari-
ate analysis were presented as adjusted odds ratios (aOR)
or point estimate with the 95 % confidence intervals (CI).
We tested for interaction to assess effect modification be-




Of the 763 patients enrolled in the study, 154 (20.2 %)
received aspirin at a dose of 81 mg daily during their
ICU stay. Table 1 presents the comparison in baseline
characteristics between aspirin and non-aspirin group.
Patients who received aspirin were older, more likely to
be males, had higher APACHE II scores, more likely to
be on statins, with higher serum creatinine, more likely
to be diabetics, with chronic cardiac, renal and respira-
tory illnesses and also with with lower platelets. When
adjusted for propensity score, all these differences be-
came insignificant.
Outcomes
Table 2 summarized the association between aspirin
therapy and mortality using multivariate analysis adjusted
for propensity score. Aspirin therapy was not associ-
ated with ICU mortality (adjusted OR 1.18, 95 % CI
0.69–2.02, P = 0.55) nor with hospital mortality (ad-
justed OR 0.95, 95 % CI 0.61–1.50, P = 0.82). On the
other hand, aspirin therapy was associated with higher
risk of ICU-acquired severe sepsis (adjusted OR 1.70,
95 % CI 1.08–2.70, P = 0.02), increased MV duration
(adjusted point estimate 2.7 days, 95 % CI 0.51–4.9, P =
Table 1 Baseline characteristics of the aspirin and non-aspirin therapy groups
Variable Aspirin N = 154 Non-aspirin N = 609 Crude P value PS adjusted P-Value
Age (yrs) mean ± SD 65 ± 16.5 48.8 ± 21.7 <0.0001 0.88
Gender, n (%)
Female 56 (36.4) 152 (25) 0.005 0.97
Male 98 (63.6) 457 (75.1)
Diabetes, n (%) 102 (66.2) 201 (33.8) 0.0001 0.22
Admission category, n (%)
Non-operative 145 (94.2) 495 (81.3) 0.0001 0.21
Post-operative 9 (5.8) 114 (18.7)
APACHE II, mean ± SD 26.5 ± 7.2 22.9 ± 8.2 <0.0001 0.67
Mechanical ventilation, n (%) 135 (87.7) 548 (90) 0.40 0.93
SOFA on day 1, mean ± SD 9.3 ± 3.3 9.2 ± 3.5 0.82 0.52
Sepsis, n (%) 47 (30.5) 147 (24.1) 0.104 0.68
Chronic respiratory disease, n (%) 43 (27.9) 114 (18.7) 0.011 0.19
Chronic cardiac disease n (%) 76 (49.4) 81 (13.3) <0.0001 0.86
Chronic liver disease n (%) 9 (5.8) 45 (7.4) 0.50 0.54
Chronic immunosuppression n (%) 11 (7.1) 55 (9.1) 0.45 0.30
Chronic renal disease n% 38 (24.7) 65 (10.7) 0.0001 0.43
GCS, mean ± SD 9.0 ± 4.2 8.6 ± 4.1 0.23 0.70
Vasopressor, n (%) 106 (68.8) 390 (64.1) 0.26 0.36
PaO2/FiO2 ratio, mean ± SD 200 ± 98 221 ± 119 0.04 0.88
Statin use n% 74 (48.1) 33 (5.4) <0.0001 0.83
Bilirubin (μmol/L), mean ± SDa 31.2 ± 69.4 36.1 ± 70 0.50 0.26
Creatinine (μmol/L), mean ± SDa 199.9 ± 171.2 148.8 ± 146.5 0.0002 0.15
INR, mean ± SD 1.5 ± 0.8 1.5 ± 0.9 0.73 0.26
Platelet, x 109/L mean ± SD 193.1 ± 121 247.9 ± 133.3 <0.0001 0.048
P-values are provided for the differences between the two groups significant before and after propensity score adjustment
APACHE Acute physiology and chronic health evaluation, GCS Glasgow coma scale, INR International normalized ratio, PS propensity score, SOFA Sequential Organ
Failure Assessment
aTo convert to conventional units in mg/dL, divide by 88.4 for creatinine and 17.1 for bilirubin
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0.02), and ICU length of stay (adjusted point estimate
2.67 days, 95 % CI 0.38–4.10, P = 0.02).
Table 3 shows the association between aspirin therapy
and all-cause hospital mortality in several subgroups of
patients. Aspirin therapy was not associated with lower
hospital mortality among any of the studied subgroups.
Discussion
The present study showed that the use of aspirin in crit-
ically ill patients was not associated with lower mortality,
but rather with increased morbidity.
Various retrospective clinical studies have shown that
low-dose aspirin was associated with reduced mortality.
Winning et al. conducted a single center retrospective
cohort study on 615 critically ill patients, 25 % of whom
were receiving antiplatelet drugs (aspirin or clopidogrel;
129 received aspirin in a dose of < 160 mg) and observed
that patients on anti-platelets had lower ICU mortality
(OR 0.19, 95 %, CI 0.12–0.33) on multivariable analysis
[29]. The same investigators conducted a study on pa-
tients with community acquired pneumonia and found a
decrease in the length of hospital stay in association with
aspirin therapy [30]. Moreover, a large cohort study of
ICU patients (n = 7,945) showed that low-dose aspirin
was associated with reduced mortality among patients
with systemic inflammatory response syndrome and
sepsis although the risk of renal injury increased [31].
On the other hand, Valerio-Rojas et al. performed a
retrospective cohort study and found that antiplatelet
therapy was not associated with decrease in hospital
mortality or ICU mortality [32]. The current study
found no statically significant difference between the
two groups in the ICU, hospital mortality after adjust-
ing for the propensity to receive aspirin therapy. Ra-
ther, our study shows aspirin use is associated with
higher risk of developing severe sepsis during ICU
stay and an increase in the duration of mechanical
ventilation and ICU length of stay.
Aspirin use has been studied for its possible effect in
reducing the risk of acute lung injury (ALI). Erlich et al.
found that pre-hospitalization antiplatelet therapy was as-
sociated with a reduced incidence of ALI (OR 0.34, 95 %
CI 0.13–0.88) [33]. Another observational study had simi-
lar findings [32]. Another ICU cohort study found that as-
pirin potentiated the effect of statins in reducing ALI and
sepsis [34]. More recently, in a secondary analysis of the
Validating Acute Lung Injury Markers for Diagnosis study,
Chen et al. found that prehospital aspirin use was associ-
ated with a decreased risk of acute respiratory distress syn-
drome (OR 0.66, 95 % CI, 0.46–0.94) [35]. However, Kor
et al. conducted a large multicenter observational
study that included 20 ICUs in the US and two ICUs
in Turkey failed to confirm the beneficial effect of
aspirin on ALI after adjusting for propensity score to
receive aspirin therapy [36]. Our study did not examine
the association with the incidence with ALI. However, it
showed higher risk of ICU-associated severe sepsis. In
addition, it showed that aspirin therapy was not associated
with lower mortality in patients with ALI (OR 1.56, 95 %
CI 0.88–2.79).
Aspirin has multiple effects in critically ill patients. As
antiplatelet drugs irreversibly inhibit platelet function,
they hinder their activation and surface expression of adhe-
sion molecules like selectins and GPIIb IIIa receptors
which are key in the formulation of microvascular
thrombus [37]. Once microvascular thrombosis is formed,
it causes ischemia that contributes to tissue injury and
multiple organ dysfunction syndrome [38, 39]. Also, plate-
let inactivation attenuates the secretion of inflammatory
mediators [7, 9], depresses their interaction with immune
cells [40] and hence modulates the adverse effects associ-
ated with the inflammatory reaction [41]. Additionally,
aspirin stimulates the synthesis of 15-epi-lipoxin A4, in





Crude odds ratio Adjusted odds ratio
OR 95 % CI P value OR 95 % CI P value
Categorical ICU mortality n (%) 32 (20.8) 95 (15.6) 1.42 0.91,2.22 0.12 1.18 0.69, 2.02 0.55
Hospital mortality n (%) 62 (40.3) 180 (29.6) 1.61 1.11,2.32 0.01 0.95 0.61, 1.50 0.82
Sepsis n (%) 56 (36.4) 256 (42.04) 0.79 0.55,1.36 0.20 1.18 0.76, 1.84 0.45
Severe sepsis n (%) 51 (33.1) 182 (29.9) 1.16 0.80,1.70 0.44 1.70 1.08, 2.70 0.02
28 day mortality n (%) 19 (30.7) 31 (17.4) 2.09 1.08,4.07 0.02 1.41 0.65, 3.05 0.39
180 day mortality n (%) 50 (34.1) 128 (22.7) 1.75 1.18, 2.60 0.005 0.72 0.43, 1.21 0.22
Continuous point estimate 95 % CI P value point estimate 95 % CI P value
MV duration (days) 11.17 ± 14.92 9.60 ± 9.05 1.58 −0.28, 3.44 0.09 2.7 0.51, 4.90 0.02
ICU LOS (days) 12.4 ± 15.2 10.8 ± 9.5 1.7 −0.27, 3.58 0.09 2.67 0.38,4.96 0.02
Hospital LOS (days) 65.6 ± 107.2 58.4 ± 81.7 7.22 −8.3, 22.7 0.36 12.5 −5.90, 30.96 0.18
CI Confidence interval, MV Mechanical ventilation, OR Odds ratio
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Table 3 Adjusted hospital mortality risk for subgroups
Variable Adjusted odds ratio 95 % confidence interval P value for interaction
All patients 0.95 0.60, 1.49 0.82
Age ≤ 58 0.76 0.25, 1.99 0.12
Age > 58 0.99 0.60, 1.67
Males 0.65 0.35, 1.21 0.26
Females 1.59 0.78, 3.24
Diabetes, yes 0.81 0.46, 1.42 0.002
no 1.09 0.52, 2.29
APACHE ≤ 23 0.37 0.13, 1.11 0.96
APACHE > 23 1.14 0.67, 1.94
Sepsis present 0.89 0.41,1.93 0.16
Sepsis absent 1.04 0.59, 1.82
Severe sepsis present 1.23 0.58, 2.60 0.12
Severe sepsis absent 0.70 0.39, 1.27
Non operative 0.95 0.60, 1.50 0.88
Post-operative 0.34 0.02, 4.43
Chronic Respiratory disease
Yes 1.18 0.54, 2.60 0.39
No 0.80 0.45, 1.42
Chronic Cardiac disease
Yes 0.92 0.47, 1.80 0.21
No 0.75 0.39, 1.43
Chronic Renal disease
Yes 0.81 0.30, 2.20 0.55
No 0.96 0.57, 1.60
Chronic liver disease
Yes 0.28 0.03, 2.24 0.21
No 1.05 0.66, 1.66
Chronic immunosuppression
Yes 0.76 0.15, 3.73 0.14
No 1.003 0.63, 1.61
Platelets × 109/L ≤ 184 0.71 0.35, 1.46 0.73
Platelets × 109/L > 184 1.34 0.74, 2.44
Bilirubin (μmol/l) ≤ 16 0.76 0.36, 1.62 0.16
Bilirubin (μmol/l) > 16 0.87 0.40, 1.90
Creatinine (μmol/l) ≤ 102 0.97 0.41, 2.28 0.39
Creatinine (μmol/l) > 102 0.83 0.49, 1.42
Statin users 1.17 0.50, 2.74 0.74
Statin non-users 0.75 0.42, 1.32
PaO2/FiO2 ratio >200 0.43 0.19,0.97 0.14
PaO2/FiO2 ratio <200 1.56 0.88,2.79
aAdjusted for propensity score which was calculated from age, sex, diabetes, admission category, APACHE, chronic respiratory disease, chronic renal disease,
chronic immunosuppression, creatinine, PaO2/FiO2 ratio, platelets, and statin use
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which it increases the synthesis of nitric oxide through
endothelial nitric oxide synthase and inducible nitric oxide
synthase [42]. Nitric oxide inhibits the interactions
between leucocytes and endothelial cells, decreasing
poly-morph neutrophil recruitment [43]. Another pu-
tative effect of aspirin is the inhibition of the nuclear
factor kappa-B [44], which plays an essential role in
immune and inflammatory responses [45]. The lack of
beneficial effect of aspirin may be a reflection of the
interaction on these multiple pathways, where a possibly
positive effect may be negated by a negative effect.
Our study should be interpreted in light of its strengths
and limitations. The strengths of our study include being a
nested cohort study within randomized controlled trials
with prospective data collection and all the patients on the
treatment group were on aspirin 81 mg. Yet, our study has
several limitations, which includes its post-hoc design with
the concern of unmeasured bias and confounders. To
overcome this concern, we performed adjusted analysis
using the propensity score. Other limitations include its
monocenter nature, and the lack of data on the duration
of aspirin therapy prior to ICU admission, cause of aspirin
prescription and data on other antiplatelet agents, platelet
transfusion, and aspirin side effects. Additionally, we have
no data on bleeding risk or the development of ALI.
Conclusions
Our study show that continuing aspirin therapy during
ICU stay was not associated with reduction in ICU or
hospital mortality in critically ill patients, but rather
with an increased morbidity. This adds to the conflict-
ing data and confirms the need for randomized, con-
trolled trials to verify the relationship between aspirin
therapy and the outcomes of critically ill patients. Cur-
rently, there is an ongoing trial of aspirin 200 mg once
daily for 14 days compared with placebo in adult patients
with severe sepsis and/or septic shock (NCT01784159).
Furthermore, another multicenter randomized clinical
trial is evaluating aspirin use in preventing ARDS
(NCT01504867). We hope that these ongoing clinical
trials will provide clear answers on the role of aspirin
therapy in critical illness.
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